Title
Kinase interest you in treating incubated cocaine-craving? A hypothetical model for treatment intervention during protracted withdrawal from cocaine

Permalink
https://escholarship.org/uc/item/46133099

Journal
Genes Brain & Behavior, 17(3)

ISSN
1601-1848

Authors
Szumlinski, KK
Shin, CB

Publication Date
2018-03-01

DOI
10.1111/gbb.12440

Peer reviewed
Kinase interest you in treating incubated drug craving? A hypothetical model for treatment intervention during protracted withdrawal.

<table>
<thead>
<tr>
<th>Journal:</th>
<th>Genes, Brain and Behavior</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>G2B-00142-2017.R1</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Review Article</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>n/a</td>
</tr>
<tr>
<td>Complete List of Authors:</td>
<td>Szumlinski, Karen; University of California, Santa Barbara, Psychological and Brain Sciences Shin, Christina</td>
</tr>
<tr>
<td>Key Words:</td>
<td>incubation, craving, mGlu1, mGlu5, prefrontal cortex, cocaine, glutamate, extinction, ERK, PKC</td>
</tr>
</tbody>
</table>
Kinase interest you in treating incubated cocaine-craving? A hypothetical model for treatment intervention during protracted withdrawal from cocaine.

Karen K. Szumlinski\textsuperscript{1,2} and Christina B. Shin\textsuperscript{1}

\textsuperscript{1}Department of Psychological and Brain Sciences, \textsuperscript{2}Department of Molecular, Cellular and Developmental Biology and the Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, CA, USA, 93106-9660.

**Running title:** ERK and cocaine craving

**Corresponding author:**
Dr. Karen K. Szumlinski
Department of Psychological and Brain Sciences
University of California Santa Barbara
MC-9660
Santa Barbara, California, USA
Telephone: +1 8058932987
Fax: +1 8058934303
Email: karen.szumlinski@psych.ucsb.edu
A diagnostic criterion for drug addiction, persistent drug-craving continues to be the most
treatment-resistant aspect of addiction that maintains the chronic, relapsing, nature of this
disease. Despite the high prevalence of psychomotor stimulant addiction, there currently exists
no FDA-approved medication for craving reduction. In good part, this reflects our lack of
understanding of the neurobiological underpinnings of drug-craving. In humans, cue-elicited
drug-craving is associated with the hyper-excitability of prefrontal cortical regions. Rodent
models of cocaine addiction indicate that a history of excessive cocaine-taking impacts
excitatory glutamate signaling within the prefrontal cortex to drive drug-seeking behavior during
protracted withdrawal. This review summarizes evidence that the capacity of cocaine-
associated cues to augment craving in highly drug-experienced rats relates to a withdrawal-
dependent incubation of glutamate release within prelimbic cortex. We discuss how stimulation
of mGlu1/5 receptors increases the activational state of both canonical and non-canonical
intracellular signaling pathways and present a theoretical molecular model in which the
activation of several kinase effectors, including PKCs, ERK and PI3K, might lead to receptor
desensitization to account for persistent cocaine-craving during protracted withdrawal. Finally,
this review discusses the potential for existing, FDA-approved, pharmacotherapeutic agents that
target kinase function as a novel approach to craving intervention in cocaine addiction.

Key Words: incubation, craving, mGlu1, mGlu5, prefrontal cortex, cocaine, glutamate,
extinction, ERK, PKC
Introduction

Persistent drug-craving continues to be the most treatment-resistant aspect of addiction that maintains the chronic, relapsing, nature of this disease. Although baseline craving (i.e., craving in the absence of any overt exteroceptive stimuli) dissipates in a time-dependent manner during withdrawal from a drug (a.k.a., abstinence), the propensity for drug-associated cues and/or contexts to elicit drug-craving increases with the passage of time during withdrawal. This intensification of cue-elicited drug-seeking is observed in both humans suffering from Substance Use Disorders and laboratory animal models of these disorders (c.f., Li et al., 2015; Pickens et al., 2011). This so-called “incubation of cue-elicited drug-craving” (hereafter referred to as “incubated craving”) was first described in cocaine-addicted humans (Gawin & Kleber, 1986), but has since been reported in humans addicted to nicotine (Bedi et al., 2011), methamphetamine (Wang et al., 2013), heroin (Wang et al., 2012) and alcohol (Li et al., 2014). As a time-dependent increase in cue-reactivity during withdrawal from drug could theoretically account for the chronic, relapsing nature of addiction, there has been a very concerted basic science research effort to understand the biobehavioral underpinnings of incubated craving.

This research effort was instigated by the seminal studies of Tran-Nguyen et al. (1998) and Grimm et al., (2001) using rat models of cocaine addiction, in which the presentation of cocaine-associated cues elicited greater “cocaine-craving” (operationally defined as conditioned operant responding or “drug-seeking behavior” in the absence of drug) during protracted withdrawal (i.e., >30 days), than that observed in early (e.g., 1 day) withdrawal. These basic behavioral findings regarding the incubation of cue-elicited cocaine-seeking have now been replicated over the past 19 years by many laboratories, using different animal species and procedural variations (c.f., Li et al., 2015; Venniro et al., 2016; Wolf, 2016). Further, incubated craving has been now been modeled in animals with histories of methamphetamine (Adhikary et al., 2017; Caprioli et al., 2017; Kransnova et al., 2014; Li et al., 2015, 2016; Scheyer et al., 2016; Shepard et al., 2004;
Venniro et al., 2017), nicotine (Funk et al., 2016; Markou et al., 2016), alcohol (Hauser et al., 2016) and opioid (Fanous et al., 2012; Li et al., 2008; Shalev et al., 2001; Theberge et al., 2012, 2013) self-administration. Typically, these incubation models involve a period of drug-taking in which rodents are trained to emit an operant response to receive access to drug (usually via an intravenous route of administration) and each drug delivery is signaled by the presentation of neutral cues (e.g., tones and lights) that come to serve as conditioned reinforcers over the course of self-administration training. Following the drug-taking phase of the study, the animals undergo “forced abstinence” during which animals remain in the home cage away from drug and the drug-associated context/cues for a designated period of time (the “withdrawal period” or “forced abstinence period”). Although there are procedural variations (c.f., Li et al., 2015; Venniro et al., 2016; Wolf, 2016), testing for incubated craving typically involves a single re-exposure to the drug-associated context, during which time operant-responding results in the presentation of the drug-associated stimuli, but no drug delivery (i.e., testing is conducted under extinction conditions). It is in these latter regards that the “classic” incubation of craving model differs from another popular model of cue-elicited drug-seeking – the extinction-reinstatement model. In the typical extinction-reinstatement model, animals are re-exposed repeatedly to the drug-associated context (quite often in the absence of drug-paired discrete cues) for many days during the drug abstinence period and responding progressively declines over time as animals undergo extinction learning. Upon reaching a particular extinction criterion, responding is then re-invigorated by re-exposure to the discrete drug-associated cues, a stressor and/or the drug itself (c.f., Sanchis-Segura & Rainer Spanagel, 2006).

Notably, incubated craving is not specific to drugs of abuse as it is observed also in rodent models of sucrose- or saccharin-taking (e.g., Aoyama et al., 2013; Counotte et al., 2014; Grimm et al., 2005, 2007, 2011a, 2011b; Uejima et al., 2007), suggesting that the neural processes underlying incubated craving may be shared across drug and non-drug reinforcers.
Interestingly, at least in rat models of cocaine-seeking, incubated craving is accompanied by a withdrawal-related impairment in the ability of the cocaine-abstinent rats to learn to suppress cue-elicited drug-seeking behavior (a.k.a. extinction learning) (Ben-Shahar et al., 2013; Grimm et al., 2003). This withdrawal-dependent impairment in extinction learning is reflected as perseverative drug-seeking behavior, even in the face of repeated re-exposure to drug-associated cues/contexts – a neurocognitive impairment theorized to contribute significantly to relapse vulnerability, particularly during late withdrawal when all signs of physical dependence have subsided (Ben-Shahar et al., 2013).

As highlighted previously (Li et al., 2015; Mueller & Cahill, 2010; Peters et al., 2009, 2013; Pickens et al., 2011), researching the mechanisms underpinning both incubated drug-craving and drug-related extinction learning is critical for understanding the neurobiological bases of the chronic, relapsing, nature of addiction. This review describes recent advances in our understanding of the role played by the excitatory amino acid neurotransmitter glutamate within the ventromedial aspect of the prefrontal cortex (vmPFC) in both of these craving-related phenomena and builds a hypothetical molecular model to account for incubated cocaine-craving, of relevance to the appropriate temporal targeting of cocaine addiction-related treatment strategies.

**Drug-craving is associated with anomalous PFC function**

The PFC commonly refers to the anterior pole of the mammalian brain and in humans (Broadman, 1912). Comprised of functionally heterogeneous subregions, the PFC is considered, very generally, to be critical for purposive actions and reasoning, particularly in the integration of cortical and subcortical inputs to instigate, modify and inhibit goal-directed behavior. Generally, the major PFC functions include: planning, decision-making and executive
attention, the latter of which is comprised of working memory (active memory), preparatory set (priming of sensory or motor regions for action) and inhibitory interference control (suppression of internal or external influences upon current action) (e.g., Miller, 2000). Thus, damage to the PFC or PFC dysfunction reduces inhibition on sensory association cortices and the underlying reward and motor circuitry, permitting habitual or compulsive behaviors to predominate. Imaging and behavioral studies in humans with Substance Use Disorders indicate morphological or functional anomalies within a number of frontal cortical structures including the anterior cingulate, dorsolateral and orbitofrontal cortex. In addition, the medial aspects of the PFC (mPFC) exhibit both gross morphological anomalies and hypo-functionality (c.f., Goldstein & Volkow, 2011) and the resultant deficits in executive functioning (including impairments in reversal learning and behavioral flexibility) is theorized to underpin the high levels of drug-craving, -seeking and -taking in this disorder (e.g., Everitt & Robbins, 2005; Jentsch & Taylor, 1999). Supporting such theories, the severity of cue- or imagery-elicited drug-craving correlates with heightened activation of mPFC subregions in those with Substance Use Disorders (e.g., Childress et al., 1993; Goldstein & Volkow, 2011; Grant et al., 1996). Such findings have led to the testable hypothesis that drug-induced neuroadaptations within mPFC render the addict especially vulnerable to the influence of drug-associated cues over internal motivational states, cognition and behavior, to drive cue-induced craving and relapse.

Indices of abnormal mPFC activation are also observed within the context of the extinction-reinstatement animal model of relapse (e.g., Hearing et al., 2008), as well as within the incubation of cocaine-seeking model of craving (e.g., Koya et al., 2009; Miller et al., 2017; Neisewander et al., 2000). Although neuronal activity within the more dorsomedial aspect of the PFC (dmPFC; anterior cingulate and dorsal prelimbic cortex; see Figure 1) appears to be critical for drug-seeking behavior within the context of drug-, stress- and cue-primed reinstatement of drug-seeking (c.f., Kalivas & McFarland, 2003; Lasseter et al., 2010), inactivation of the
ventromedial aspect of the PFC (vmPFC; which in our rat studies includes the ventral prelimbic and infralimbic cortices in rat; see Figure 1) abolishes incubated cocaine-craving (Koya et al., 2009). Further, optogenetic data indicate a more critical role for the prelimbic cortical projections to the nucleus accumbens core in this regard (Ma et al., 2014). Moreover, incubated cocaine-craving in rats is not affected by pharmacological disruption of neuronal activity within the dmPFC (Koya et al., 2009). These results are consistent with evidence that neurons within the prelimbic cortex, but not other PFC subregions, exhibit a cocaine withdrawal-dependent strengthening of their encoding of cocaine-associated stimuli (e.g., West et al., 2014) and that cue-elicited activation of prelimbic cortex (indexed by kinase activity) increases as a function of the time during cocaine abstinence (Koya et al., 2009; Miller et al., 2017). Such findings argue that withdrawal-dependent prelimbic hyperactivity invigorates cocaine-seeking in response to cue-elicited internal motivational states to drive incubated cocaine-seeking behavior during protracted withdrawal.

The Glutamatergic Basis of Cocaine-Craving

The principle excitatory neurotransmitter of the pyramidal efferents from the cortex is glutamate and, thus, glutamate is also the principle neurotransmitter of homo- and heterotopical cortical afferents to mPFC. Several thalamic nuclei, as well as the hippocampus, send dense glutamatergic projections to mPFC subregions and this neuroanatomical organization well-positions glutamate as the prime driver of cue-elicited prelimbic cortex hyper-excitability in drug-craving individuals (Sun & Rebec, 2006). Thus, we posited that time-dependent changes in glutamate-dependent activation of prelimbic cortex is likely involved in the incubation of drug-craving and perhaps also the extinction learning deficits that occur during protracted abstinence.
To date, we have addressed this hypothesis within the context of incubated cocaine-seeking as discussed below.

Glutamate activates 3 subtypes of cation-gating inotropic receptors that include the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), N-methyl-D-aspartate (NMDA) and Kainate receptors. In addition, glutamate stimulates 8 different subtypes of metabotropic glutamate (mGlu) receptors that differentially influence cellular function based on their synaptic localization and coupling to intracellular effectors (c.f., Szumlinski & Woodward, 2013). Although over a decade of basic science research has studied cocaine-induced dysregulation of corticostriatal glutamate transmission for behavioral sensitization, drug/cue/stress-induced relapse and incubation of cocaine-craving (c.f., D'Souza, 2015; Loweth et al., 2014; Quintero, 2013; Wolf, 2016), there has been relatively little published research characterizing how abstinence from a history of cocaine-taking impacts biochemical indices of glutamate transmission within the mPFC proper. However, while some discrepancy exists in the literature, many studies have reported that repeated, experimenter-administered cocaine injections increase indices of mPFC glutamate, including: extracellular glutamate content, glutamate receptor expression, and the regulation of extracellular glutamate by Gαq/11-coupled mGlu1/5 and Gαi/o-coupled mGlu2/3 receptors (e.g., Ary & Szumlinski, 2007; Baker et al., 2003; Steketee & Kalivas, 2011; Timmer & Steketee, 2013). Importantly, when examined, the cocaine injection-induced changes in mPFC glutamate tend to manifest as a function of time following the removal of drug (e.g., Steketee & Kalivas, 2011). Yet, how these glutamate-related biochemical adaptations arise, whether or not they are interrelated, and how they influence psychomotor reactivity to cocaine-conditioned stimuli of relevance to cocaine-craving remain to be determined.
In contrast, the majority of studies employing animal models of intravenous cocaine self-administration indicate that a cocaine history blunts mPFC glutamate function, in a manner consistent with the reported hypofrontality in humans suffering from Cocaine Use Disorder discussed above. For example, rats with a history of cocaine self-administration exhibit lowered extracellular glutamate content within the prelimbic cortex of the mPFC when assayed at 24 h withdrawal and the magnitude of this reduction increases as a function of the amount of cocaine self-administered (Ben-Shahar et al., 2012). Such data are consistent with the hypothesis that a cocaine-dependent decline in mPFC extracellular glutamate might drive “uncontrollable” cocaine-taking. However, the immunoblotting work to date reveals little overlap in the effects of cocaine-taking upon extracellular glutamate levels and the protein expression of Group1 mGlu receptors and NMDA receptor (NMDAR) subunits (Ben-Shahar et al., 2009). Further, although rats with an extensive cocaine-taking history exhibit an impairment in the capacity of the drug to lower extracellular glutamate within the prelimbic cortex in early withdrawal (Ben-Shahar et al., 2012) and a blunting of mGlu2/3-dependent long-term depression within neurons of prelimbic cortex also in early withdrawal (Kasanetz et al., 2013), there is little evidence that cocaine self-administration alters the protein expression of mGlu2/3 receptors within vmPFC during either early or later withdrawal (Szumlinski, 2016). Thus, although intact vmPFC function is required for extinction of both appetitive and aversive conditioning (c.f., Peters et al., 2009) and mGlu1/5 receptor activation, in particular, is important for cocaine-related extinction learning (e.g., Gass & Olive, 2009), the large majority of animal studies examining for changes in mPFC glutamate receptor expression following a history of intravenous cocaine self-administration have yielded negative results (Ben-Shahar et al., 2009, 2013; Hao, Martin-Fardon, & Weiss, 2010; Ghasemzadeh, Vasudevan, Giles, Purgianto, Seubert, & Mantsch, 2011).

Cue-induced Glutamate Adaptations within vmPFC of Relevance to Incubated Cocaine-Craving
It is notable, however, that in all of the abovementioned reports, rats were not re-exposed to the cocaine self-administration environment or to discrete cues associated with cocaine-taking/availability prior to tissue collection for protein assessment during withdrawal from cocaine. However, such re-exposure appears to be an important determinant of the manifestation of receptor protein changes, at least in the case of mGlu1/5 receptors. For example, a study by Ghasemzadeh et al. (2011) failed to observed changes in vmPFC expression of mGlu1/5 when cocaine-experienced rats had undergone extensive extinction training over the course of 10 days following withdrawal from cocaine. Interestingly, a study employing a similar cocaine self-administration protocol, following which rats underwent only a single 2-h extinction session in a test for incubated cocaine-craving, reported reduced mGlu1/5 expression within vmPFC, but only in rats re-exposed to cocaine-associated stimuli and allowed to engage in cue-reinforced responding during protracted (i.e., 30 days) withdrawal (Ben-Shahar et al., 2013). Moreover, a very strong inverse correlation exists between the magnitude of the cue-reinforced cocaine-seeking and vmPFC expression of mGlu1/5 (Miller et al., 2017). In contrast, no changes in vmPFC mGlu1/5 expression were observed in rats with equivalent cocaine self-administration experience but left undisturbed in the home cage prior to tissue collection (Ben-Shahar et al., 2013). Thus, for mGlu1/5 (and perhaps other glutamate receptors), the regulation of protein expression within vmPFC is complex, involving interactions between cocaine self-administration history, the duration of time following withdrawal from cocaine, and the number of times animals are re-exposed to cocaine-associated stimuli and/or afforded the opportunity to engage in cue-reinforced behavior in the absence of the drug.

Despite the strong inverse relationship exists between vmPFC mGlu1/5 expression and the manifestation of cocaine-seeking (Miller et al., 2017), pharmacological manipulation of mGlu1/5 function within neither vmPFC nor dmPFC influences cue-reinforced responding when rats are
tested immediately post-infusion for cue-reinforced responding during either early or later withdrawal from cocaine (Ben-Shahar et al., 2013). These findings argue that mGlu1/5 function within vmPFC does not actively regulate cue-reinforced cocaine-seeking per se. However, when these same rats are assayed for cue-reinforced cocaine-seeking the day following microinfusion, prior mGlu1/5 inhibition blunts the extinction learning that is manifested by the rats in early withdrawal (Ben-Shahar et al., 2013). The extinction impairment induced in cocaine-experienced rats by intra-vmPFC mGlu1/5 antagonist infusion during early withdrawal from cocaine appears to reflect interference with extinction memory consolidation as the carry-over effects of intra-vmPFC mGlu1/5 antagonist microinjection are comparable in rats infused immediately prior to or immediately following the initial test for cue-reinforced cocaine-seeking (Ben-Shahar et al., 2013). Conversely, stimulating vmPFC mGlu1/5 function via a local agonist infusion facilitates extinction learning when rats in protracted withdrawal are tested for drug-seeking behavior the day following microinfusion (Ben-Shahar et al., 2013). These neuropharmacological results demonstrate a necessary and active role for decreased vmPFC mGlu/5 receptor function in regulating the extinction impairment observed during protracted withdrawal from cocaine and are reminiscent of findings from the fear-conditioning literature (e.g., Fontanez-Nuin et al., 2011). Together, such data argue an important role for intact vmPFC mGlu1/5 in the general mechanisms of inhibitory learning, although it remains to be determined whether or not the observed effects of vmPFC mGlu1/5 manipulations (Ben-Shahar et al., 2013; Fontanez-Nuin et al., 2011) generalizes to other addictive substances. Nevertheless, Group 1 mGlu receptor stimulation can augment inhibitory currents within PFC to a greater degree than excitatory currents (Sun & Neugebauer, 2011), arguing that the time- and learning-dependent reduction in vmPFC mGlu1/5 function/expression reported in incubated rats (Ben-Shahar et al., 2013) may disinhibit glutamatergic output from the vmPFC to instigate a feedforward mechanism of neuronal hyperexcitability that promotes the saliency of drug-associated cues and high levels of cocaine-craving during protracted abstinence.
As reviewed previously (c.f., Steketee & Kalivas, 2010), considerable *in vivo* microdialysis research supports a hyperexcitability of corticostratial efferents upon cocaine re-exposure (a.k.a. priming), with data derived primarily from studies of cocaine-induced behavioral sensitization and the extinction-reinstatement model of relapse. In contrast, very few reports describe the glutamate cue/context reactivity of corticostratial pathways in cocaine-experienced animals whose drug-seeking behavior has not be deliberately extinguished via repeated re-exposure to drug-associated stimuli (Bell et al., 2000; Hotsenpiller et al., 2001; Suto et al., 2010). However, consistent with the notion that incubated cocaine-craving may reflect a disinhibition of glutamatergic output from the vmPFC, re-exposure to cocaine-associated cues following a brief (1-day) period of drug abstinence is sufficient to elicit a large increase in extracellular glutamate within nucleus accumbens subregions (Suto et al., 2010) and re-exposure to cocaine-associated contexts facilitates cocaine-induced glutamate release within these subregions (Bell et al., 2000). In more direct support of a time-related dysregulation of extracellular glutamate within the vmPC proper, Shin et al. (2016) examined how responding for neutral (saline-paired), sucrose- and cocaine-paired cues affected vmPFC glutamate levels during early versus later withdrawal (3 versus 30 days, respectively). Interestingly, only cocaine-experienced rats in later withdrawal (i.e., rats exhibiting incubated cocaine-seeking) demonstrated a marked cue-elicited rise in vmPFC glutamate. These data provided the first evidence that the cue-reactivity of glutamate terminals within the vmPFC incubates during protracted withdrawal. Further, a strong positive correlation existed between the magnitude of cue-induced drug-craving and the amount of glutamate release observed in the behaving rats (Shin et al., 2016). This correlation strengthens the notion that time-dependent neuroadaptations within glutamate efferents to the vmPFC and the activation of non-mGlu1/5 glutamate receptors might drive the cue-hyper-reactivity of cocaine-incubated rats. In support of this assertion, a recent study revealed that inhibition of vmPFC glutamate release, specifically
within the prelimbic cortex, is sufficient to blunt incubated cocaine-seeking during protracted, but not early, withdrawal from cocaine (Shin et al., 2017). The questions remain as to the identities of the glutamatergic afferents to the prelimbic cortex that undergo plasticity during protracted withdrawal from cocaine and the specific post-synaptic glutamate receptors activated by this time-dependent incubation of cue-elicited glutamate release within vmPFC.

**Targeting PKCɛ Activity to Prevent mGlu1/5 Desensitization and Associated Inhibitory Learning Deficits**

As discussed above, although the relatively limited neuropharmacological data to date negates a role for reduced mGlu1/5 receptor activation within vmPFC as important for the manifestation of drug-seeking per se, the time-dependent down-regulation of these receptors appears to impair inhibitory learning, which we theorize perpetuates high levels of drug-seeking behavior even during protracted withdrawal from cocaine (Ben-Shahar et al., 2013). As such, it is important to try to understand the molecular underpinnings of the observed mGlu1/5 down-regulation as a failure to learn to inhibit craving (and actions driven by that craving) upon re-exposure to drug-related stimuli obviously poses a massive barrier to addiction recovery.

mGlu1/5 receptors are well-described to undergo rapid desensitization upon stimulation (e.g., Bradley & Chaliss, 2011; Gereau & Heinemann, 1998). The fact that re-exposure to cocaine-associated cues during protracted withdrawal (i.e., in rats exhibiting incubated responding) elicits a temporally coincident increase in extracellular glutamate (Shin et al., 2016) and reduction in mGlu1/5 expression (Ben-Shahar et al., 2013) is suggestive of a causal relation. The rapid desensitization of mGlu1/5 involves receptor phosphorylation by either G-protein receptor kinases or protein kinase C (PKC) isozymes (e.g., Bradley & Chaliss, 2011; Gereau & Heinemann, 1998). In the case of PKC-dependent desensitization, phosphorylation of mGlu5 at
Ser<sup>839</sup> by the atypical (i.e., calcium-independent) PKCε isoyme results in the uncoupling of the receptor from Gα<sub>q/11</sub>, at least when assayed in cultured cortical astrocytes (Bradley & Chaliss, 2011). This result is very interesting based on the large body of literature implicating PKCε, and its activation by mGlu5 stimulation, in the neurobiology of drug addiction (c.f., Olive & Newton, 2010). Indeed, very recent studies by Miller et al. (2017) revealed a positive correlation between incubated cocaine-craving and PKCε phosphorylation within vmPFC and in support of a potential link between PKCε activity and mGlu1/5 desensitization, PKCε phosphorylation (an index of enzyme priming) was inversely correlated with mGlu1/5 expression within the vmPFC of cocaine-experienced rats (Miller et al., 2017). Importantly, the transient inhibition of PKCε translocation within the vmPFC not only blunted the manifestation of incubated cocaine-craving in rats tested for incubated craving during protracted cocaine abstinence, but a residual inhibition of responding was observed on a second test conducted the next day (Miller et al., 2017). Of note, the inhibition of PKCε translocation within vmPFC did not affect drug-seeking behavior when assayed in early withdrawal from cocaine, which may reflect a floor effect upon kinase activity, as cocaine-experienced rats exhibit relatively low levels of phosphorylated PKCε within the vmPFC during early withdrawal from the drug (Miller et al., 2016).

These recent results have led to one hypothetical model (Figure 1) in which incubated cocaine-craving involves a time-dependent increase in the cue-reactivity of glutamate terminals within vmPFC – the mechanism(s) for which remain to be explored. This cue-hyper-reactivity, in turn, stimulates the activation of perisynaptic Group1 mGlu receptors, instigating negative feedback loops involving PKCε activation and the uncoupling of mGlu1/5 from Gα<sub>q/11</sub> (and perhaps also the recruitment of GRKs). Consequently, mGlu1/5 internalizes and is degraded, resulting in lower protein expression. As the “anti-craving” effects of PKCε inhibition are only apparent when rats are pretreated with the kinase inhibitor 20 min prior to the initial test for drug-craving and not immediately prior (Miller et al., 2017), the PKCε-mediated G-protein uncoupling of mGlu1/5...
is theorized to impair the acquisition of extinction learning during the initial cue re-exposure, with mGlu1/5 degradation theorized to compound the extinction deficit by impairing the consolidation of this learning (Ben-Shahar et al., 2013). Consequently, cocaine-experienced individuals in protracted withdrawal have greater difficulty suppressing craving in response to both the acute and repeated re-exposure to drug-associated cues, and this extinction impairment ultimately renders these individuals highly susceptible to cue-elicited relapse even during protracted abstinence. This hypothetical model poses strategies aimed at either preventing mGlu1/5 desensitization within vmPFC as potentially effective approaches for curbing incubated craving in protracted withdrawal. Consistent with this hypothetical model, inhibiting incubated glutamate release within the vmPFC using mGlu2/3 agonists (Shin et al., 2017) or inhibiting PKCɛ priming (Miller et al., 2017) both blunt incubated responding upon initial cue re-exposure, while pharmacologically stimulating mGlu1/5 activity during that initial cue re-exposure enables normal extinction learning to occur, thereby attenuating cue-reactivity upon subsequent drug cue re-exposure (Ben-Shahar et al., 2013).

TARGETING ERK ACTIVITY TO PREVENT mGLU1/5 DESENSITIZATION AND ASSOCIATED INHIBITORY LEARNING DEFICITS?

In addition to PKCɛ and various GRKs, mGlu1/5 can be phosphorylated also by a number of other kinases upon the activation of various neurotransmitter receptors, including the D1 dopamine receptor (D1R), the NMDA receptor, and the tyrosine kinase B receptor (TrkB; receptor for brain-derived neurotropic factor or BDNF) (e.g., Park et al., 2013). Interestingly, D1R or TrkB stimulation induces mGlu5 phosphorylation at Thr^{1123} and Ser^{1126}, which lie within the Homer binding domain of the receptor (Park et al., 2013). As reviewed elsewhere (e.g.,
Shiraishi-Yamaguchi & Furuichi, 2007), Homers constitute a family of scaffolding proteins that are encoded by 3 genes (Homer1-3) and members of this family are critical for mGlu1/5 trafficking and localization, as well as the coupling to intracellular effectors and regulation of various cation channels. During withdrawal from cocaine, the protein expression of the constitutively expressed Homer2 isoform is upregulated within vmPFC and the resultant imbalance between Homer1 and Homer2 isoforms within this region critically regulates cocaine-conditioned reward in mice and cocaine-primed reinstatement of cocaine-seeking in rats (Ary et al., 2013; Gould et al., 2015). Proline-directed kinases, including extracellular signal-regulated kinase (ERK), phosphorylates mGlu5 within the Homer binding domain (e.g., Park et al., 2013) and the phosphorylation of mGlu5(Ser\textsuperscript{1126}) recruits an additional scaffolding protein, Preso1, with the dynamic interaction between this protein triad augmenting the receptor affinity for Homers > 10-fold (Park et al., 2013).

We argue that the interactions between ERK and mGlu5 (and possibly also mGlu1) within vmPFC is possibly relevant to persistent cocaine-seeking in protracted withdrawal as incubated cocaine-craving is associated with increased ERK activity within vmPFC (Koya et al., 2009) and glutamate and BDNF release within the terminal regions of corticofugal projections contributes to the incubation of drug-craving (c.f., Li et al., 2015; Li & Wolf, 2015; Pickens et al., 2001). Although direct local inhibition of ERK within vmPFC does not alter the magnitude of incubated cocaine-seeking (Koya et al., 2009), the role for ERK and ERK-dependent phosphorylation of Group1 mGlu receptors in the extinction resistance that accompanies incubated craving has not yet been explored. Thus, we propose another hypothetical model (Figure 2) relating time-dependent changes in cue-elicited BDNF and/or glutamate release within the vmPFC to the strengthening of mGlu1/5-Homer-ERK interactions facilitating mGlu1/5 desensitization by both homologous and heterologous mechanisms. More specifically, incubated glutamate release and/or the recruitment of BDNF/TrkB activation within the vmPFC can stimulate mitogen-
activated protein kinase (MAPK) signaling either directly or indirectly through activation of a variety of second or third messengers systems, resulting in increased ERK activity (c.f., Cahill et al., 2014; Sun et al., 2016). This hyper-activated ERK can then phosphorylate mGlu1/5 within the Homer binding domain via an interaction with Preso1 (e.g., Park et al., 2013), increasing both the affinity of the receptors for constitutively expressed Homer proteins (Park et al., 2013) and the probability of receptor desensitization (Minami et al., 2003). This probability of receptor desensitization is increased during protracted drug withdrawal secondary to the elevated expression of constitutively expressed Homer expression within vmPFC (e.g., Gould et al., 2013). Alternatively, it is conceivable that hyper-phosphorylation of mGlu1/5 by ERK, PKCs and/or other kinases, incl. PI3K (Szumlinski et al., 2017) might instigate GRK/arrestin pathways for mGlu1/5 internalization and degradation, leading to neurocognitive dysfunction.

INSERT FIGURE 3 ABOUT HERE

ERK activation induces also an increase in the transcription of the immediately early, truncated, Homer isoform Homer1a (c.f., Szumlinski et al., 2008). Homer1a induction typically serves a dominant negative function, dismantling constitutive Homer protein scaffolding (c.f., Shiraishi-Yamaguchi & Furuichi, 2007) and receptor coupling to intracellular effectors. Homer1a is robustly induced by acute cocaine (Ghasemzadeh et al., 2009), raising the possibility that an ERK-dependent induction of Homer1a during early drug exposure serves normally to counteract any influence this kinase may have upon mGlu-Homer binding and receptor desensitization. However, the capacity of cocaine to induce Homer1a expression appears to develop tolerance with repeated drug exposure (Ghasemzadeh et al., 2009). Although the mechanism(s) involved in this tolerance are not known, one possibility may involve a shunting of ERK activity away from the nucleus by a drug-induced increase in ERK binding to Preso1 (Park et al., 2013). The ERK/Preso1-mediated strengthening of Homer scaffolding with mGlu1/5, coupled with the
increased Homer2 expression (Gould et al., 2015) and reduced Homer1a expression (Ghasemzade et al. 2009), are predicted to increase the activational state of canonical and non-canonical signaling pathways leading to rapid mGlu5 internalization/degradation and extinction resistance.

**Concluding Remarks and Future Directions**

Incubated cue-elicited drug-craving is a clinically relevant phenomenon observed across drugs of abuse that co-occurs, at least in an animal model of cocaine addiction, with deficits in the ability to learn to suppress conditioned drug-seeking behavior. Currently, no clinically approved pharmacotherapeutic exists for craving reduction in cocaine addiction. Based on the extant literature, this article presented hypothetical models relating a kinase-dependent desensitization of mGlu1/5 within the vmPFC to the time- and context-dependent preservative cocaine-craving during protracted withdrawal. From these models, a number of possible treatment strategies emerge that all have, at their core, the goal of maintaining normal mGlu1/5 function within vmPFC. These strategies include: reducing the excitability of glutamate terminals glutamate release within vmPFC, which may be achieved via stimulation of autoreceptors (Shin et al., 2017); augmenting mGlu1/5 function via treatment with positive allosteric modulators (Ben-Shahar et al., 2013); administration of TrkB, D1 or ionotropic glutamate receptor antagonists to prevent their induction by BNDF, dopamine, and glutamate, respectively; treatment with small molecule inhibitors of mGlu1/5-Homer scaffolding; and inhibition of intracellular effectors known to participate in the desensitization of mGlu1/5 function. With respect to the latter, this can be achieved via the administration of: selective or non-selective inhibitors of ERK, PKCs and/or PI3K (Miller et al., 2017; Szumlinski et al., 2017) and it is notable that pharmaceutical agents targeting all 3 of these kinases, either alone or in combination, are either FDA-approved, or in
Phase II/III clinical trials, as chemotherapies for treating a wide range of cancers, as well as wound healing & chronic pain (Asati et al., 2016; Jokinen & Koivunen, 2015; Sun et al., 2015).

While these hypothetical models are based, in part, on circumstantial evidence derived exclusively from rodent models of incubated cocaine-seeking, they nevertheless provide a theoretical foundation upon which to base exploration of the molecular biology of incubated drug-craving and associated learning impairments of relevance to the design of effective treatment interventions for relapse prevention and addiction recovery.

Disclosure: The authors have no financial interests to disclose. No external funds were employed in the composition of this review article.
References


Figure Legends

**Figure 1:** Schematic of the subregions and dorsal-ventral subdivision of the medial PFC discussed in this review. Coronal section through the medial PFC (mPFC) of the rat brain derived from the rat brain atlas of Paxinos and Watson (2006) highlighting the location of the infralimbic (IL), prelimbic (PL), anterior cingulate cortex (Cg1) and secondary motor cortex (M2). In the rodent literature, the mPFC is sometimes subdivided along the ventral-dorsal plane into a dorsomedial subregion (dmPFC), which includes Cg1 and the more dorsal aspect of the PL, and a ventromedial subregions (vmPFC), which includes the more ventral aspect of the PL and the IL.

**Figure 2:** Hypothetical Molecular Model Relating Incubated Glutamate Release and Canonical Signaling Through mGlu1/5 Receptors in Extinction Resistance. (A) The capacity of drug-associated stimuli to elicit glutamate release within the vmPFC incubates during protracted withdrawal, resulting in an over-stimulation of post-synaptic mGlu1/5 receptors. (B) mGlu1/5 stimulation results in the activation of various PKCs, of which the PKCɛ isozyme is well characterized to phosphorylate the receptor, which recruits β-arrestin. (C) β-arrestin recruitment activates receptor internalization mechanisms, reducing cell surface expression and (D) receptor degradation. While insufficient to induce incubated craving, the reduction in functional mGlu1/5 is sufficient to induce a deficit in inhibitory learning and a failure to learn to suppress drug-craving and behaviors driven by that craving.

**Figure 3:** Hypothetical Molecular Model Relating Incubated ERK Activation to mGlu1/5 Receptor-Dependent Extinction Resistance. (A) Time-dependent incubation of cue-elicited glutamate release, coupled with the recruitment of BDNF, activates a number of intracellular effectors that ultimately augment the activational state of ERK (in addition to or because of the
stimulation of PKCs and PI3K). (B) Activated ERK phosphorylates mGlu in the Homer binding domain and recruits Preso1, increasing Homer coupling to the receptor. As the Homer2 isoform is selectively over-expressed during protracted withdrawal, it is presumed that ERK/Preso1 interactions with mGlu receptors augments Homer2-mGlu1/5 interactions and shunts activated ERK away from the nucleus. (C) The increased Homer2 binding to mGlu1/5 is predicted to facilitate canonical and non-canonical signaling through mGlu1/5, including the activation of PKC isozymes and PI3K. As illustrated in Figure 1, this kinase activation results in mGlu1/5 internalization leading to impaired extinction learning and memory and persistent cue-elicited drug craving.
Figure 1: Schematic of the subregions and dorsal-ventral subdivision of the medial PFC discussed in this review. Coronal section through the medial PFC (mPFC) of the rat brain derived from the rat brain atlas of Paxinos and Watson (2006) highlighting the location of the infralimbic (IL), prelimbic (PL), anterior cingulate cortex (Cg1) and secondary motor cortex (M2). In the rodent literature, the mPFC is sometimes subdivided along the ventral-dorsal plane into a dorsomedial subregion (dmPFC), which includes Cg1 and the more dorsal aspect of the PL, and a ventromedial subregions (vmPFC), which includes the more ventral aspect of the PL and the IL.

190x107mm (300 x 300 DPI)
Figure 2: Hypothetical Molecular Model Relating Incubated Glutamate Release and Canonical Signaling Through mGlu1/5 Receptors in Extinction Resistance. (A) The capacity of drug-associated stimuli to elicit glutamate release within the vmPFC incubates during protracted withdrawal, resulting in an over-stimulation of post-synaptic mGlu1/5 receptors. (B) mGlu1/5 stimulation results in the activation of various PKCs, of which the PKCε isozyme is well characterized to phosphorylate the receptor, which recruits β-arrestin. (C) β-arrestin recruitment activates receptor internalization mechanisms, reducing cell surface expression and (D) receptor degradation. While insufficient to induce incubated craving, the reduction in functional mGlu1/5 is sufficient to induce a deficit in inhibitory learning and a failure to learn to suppress drug-craving and behaviors driven by that craving.
Figure 3: Hypothetical Molecular Model Relating Incubated ERK Activation to mGlu1/5 Receptor-Dependent Extinction Resistance. (A) Time-dependent incubation of cue-elicited glutamate release, coupled with the recruitment of BDNF, activates a number of intracellular effectors that ultimately augment the activational state of ERK (in addition to or because of the stimulation of PKCs and PI3K). (B) Activated ERK phosphorylates mGlu in the Homer binding domain and recruits Preso1, increasing Homer coupling to the receptor. As the Homer2 isoform is selectively over-expressed during protracted withdrawal, it is presumed that ERK/Preso1 interactions with mGlu receptors augments Homer2-mGlu1/5 interactions and shunts activated ERK away from the nucleus. (C) The increased Homer2 binding to mGlu1/5 is predicted to facilitate canonical and non-canonical signaling through mGlu1/5, including the activation of PKC isozymes and PI3K. As illustrated in Figure 1, this kinase activation results in mGlu1/5 internalization leading to impaired extinction learning and memory and persistent cue-elicited drug craving.